525,750 Shares in Pharvaris N.V. $PHVS Purchased by Elmind Capital LP

Elmind Capital LP bought a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 525,750 shares of the company’s stock, valued at approximately $18,180,435,000. Pharvaris accounts for about 4.6% of Elmind Capital LP’s investment portfolio, making the stock its 7th largest position. Elmind Capital LP owned 0.80% of Pharvaris at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PHVS. Quantbot Technologies LP purchased a new position in Pharvaris during the second quarter valued at approximately $41,000. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. Barclays PLC bought a new stake in Pharvaris during the 4th quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Pharvaris in the 4th quarter valued at $86,000. Finally, CoreCap Advisors LLC purchased a new position in shares of Pharvaris in the 2nd quarter valued at $93,000.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $37.23 on Wednesday. The business’s 50-day moving average is $34.40 and its 200 day moving average is $30.56. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $38.13. The firm has a market capitalization of $2.44 billion, a P/E ratio of -12.21 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts expect that Pharvaris N.V. will post -3.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PHVS. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a report on Thursday, August 13th. New Street Research set a $60.00 price target on shares of Pharvaris in a research report on Friday, August 14th. UBS Group set a $74.00 price objective on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Citizens Jmp boosted their price objective on shares of Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.08.

Insider Activity at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the sale, the insider owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anna Nijdam sold 2,670 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the transaction, the insider owned 46,275 shares in the company, valued at $1,428,509.25. The trade was a 5.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 121,325 shares of company stock valued at $4,270,425 over the last 90 days.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.